Change of Directors Interest Notice - Dr Charmaine Gittleson
Released
Released
Announcement PDF
Appendix 3Y
Change of Director’s Interest Notice
Appendix 3Y
Rule 3.19A.2
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity – Percheron Therapeutics Limited
ABN – 41 095 060 745
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for
the director for the purposes of section 205G of the Corporations Act.
Name of Director
Charmaine Gittleson
Date of last notice
31 December 2024
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should
be disclosed in this part.
Direct or indirect interest
Indirect
Nature of indirect interest
(including registered holder)
Director
of
related
Investments Pty Ltd)
Date of change
20 May 2025
No. of securities held prior to change
Indirect
Fully paid ordinary shares
2,399,999
Note: Provide details of the circumstances giving rise to the relevant
interest.
entity
(Gittleson
Class
Unquoted options
3,000,000 exercisable at 6.1c per option on or
before 30 June 2028.
Unquoted options
Number acquired
239,999
Number disposed
Value/Consideration
Nil
$0.035 per option
Note: If consideration is non-cash, provide details and estimated
valuation
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 1
Appendix 3Y
Change of Director’s Interest Notice
No. of securities held after change
Indirect
Fully paid ordinary shares
2,399,999
Unquoted options
3,000,000 exercisable at 6.1c per option on or
before 30 June 2028.
Nature of change
Example: on-market trade, off-market trade, exercise of options,
issue of securities under dividend reinvestment plan, participation in
buy-back
239,999 exercisable at 3.5c per option on or
before 20 May 2028.
Unquoted options issued under Percheron
Therapeutics Bonus Offer as detailed in the
prospectus lodged with ASIC on 6 May 2025
and the ASX on 7 May 2025.
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should
be disclosed in this part.
Detail of contract
Not applicable
Nature of interest
Not applicable
Name of registered holder
(if issued securities)
Date of change
Not applicable
Not applicable
No. and class of securities to which Not applicable
interest related prior to change
Note: Details are only required for a contract in
relation to which the interest has changed
Interest acquired
Not applicable
Interest disposed
Not applicable
Value/Consideration
Not applicable
Interest after change
Not applicable
Note: If consideration is non-cash, provide details
and an estimated valuation
Part 3 – +Closed period
Were the interests in the securities or contracts detailed No
above traded during a +closed period where prior written
clearance was required?
If so, was prior written clearance provided to allow the trade Not applicable
to proceed during this period?
If prior written clearance was provided, on what date was this Not applicable
provided?
+ See chapter 19 for defined terms.
Appendix 3Y Page 2
01/01/2011
Share your feedback
Discover